SRB-18

N/A

Report date: 2025/01/26 16:43:16

Base Information

Drug NameSRB-18
Drug Alias Nameanti-HER3/anti-TRAIL bispecific antibody (Sunrock Biopharma)SRB-18
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsTumor necrosis factor ligand superfamily member 10 modulators
TargetsReceptor tyrosine-protein kinase erbB-3Tumor necrosis factor ligand superfamily member 10
Therapy Area/IndicationsHead and Neck NeoplasmsStomach NeoplasmsColonic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSunRock Biopharma SL
China Registration ClassN/A

Develop Information

Active CompaniesSunRock Biopharma SL
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsStomach NeoplasmsColonic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A